Moreover, production of these antibodies can be genetically driven, and can begin during early childhood, as attested by their presence in almost all patients with autoimmune polyendocrine syndrome type-1 (APS-1) due to germline mutations of AIRE (17–19). This evidence concerns the gene AIRE and autoimmune polyendocrine syndrome type 1.